Investment Thesis
Stryker demonstrates solid fundamental strength with 11.2% revenue growth, healthy profitability margins (63.3% gross, 15.5% operating), and strong free cash flow generation of $415M. However, critically low ROE (3.2%) and ROA (1.6%) reflect significant capital efficiency challenges, while decelerating net income growth (8.5% vs 11.2% revenue growth) signals emerging operating leverage concerns that require monitoring.
Strengths
- Strong double-digit revenue growth (11.2% YoY) in stable medical device sector
- Solid profitability margins across gross (63.3%), operating (15.5%), and net (12.4%) levels
- Robust free cash flow generation ($415M) with 70% conversion from net income
- Healthy liquidity position with current ratio of 2.11x and quick ratio of 1.25x
- Moderate leverage (0.62x debt/equity) with adequate interest coverage (6.6x)
Risks
- Critically low return on equity (3.2%) and return on assets (1.6%) indicating poor capital efficiency
- Net income growth (8.5%) significantly lagging revenue growth (11.2%) suggesting cost pressures or integration challenges
- Elevated debt burden ($14.2B) relative to modest cash position ($2.9B) limiting financial flexibility
- Potential margin compression as operating leverage fails to materialize from revenue growth
- Low return on capital may be insufficient to justify shareholder investments
Key Metrics to Watch
- Operating margin trend and SG&A expense ratio
- Return on equity progression and capital efficiency improvements
- Free cash flow sustainability and debt reduction trajectory
- Revenue growth quality and segment profitability performance
Financial Metrics
Revenue
6.0B
Net Income
745.0M
EPS (Diluted)
$1.93
Free Cash Flow
415.0M
Total Assets
46.3B
Cash
2.9B
Profitability Ratios
Gross Margin
63.3%
Operating Margin
15.5%
Net Margin
12.4%
ROE
3.2%
ROA
1.6%
FCF Margin
6.9%
Balance Sheet & Liquidity
Current Ratio
2.11x
Quick Ratio
1.25x
Debt/Equity
0.62x
Debt/Assets
50.4%
Interest Coverage
6.59x
Long-term Debt
14.2B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-12T06:48:07.738073 |
Data as of: 2026-03-31 |
Powered by Claude AI